ストックスクリーナーアプリを入手
725.72
4.21%
-31.88
アフターアワーズ：
728.05
2.33
+0.32%
前日終値:
$757.60
開ける：
$747.83
24時間の取引高:
5.39M
Relative Volume:
1.44
時価総額：
$689.73B
収益：
$40.86B
当期純損益:
$8.37B
株価収益率:
78.46
EPS:
9.25
ネットキャッシュフロー:
$-2.28B
1週間 パフォーマンス:
-9.27%
1か月 パフォーマンス:
-6.79%
6か月 パフォーマンス:
-19.86%
1年 パフォーマンス:
+15.39%
1日の値動き範囲:
$725.01
$755.28
1週間の範囲:
$725.01
$805.34
52週間の値動き範囲:
$612.70
$972.53
Lilly Eli Co Stock (LLY) Company Profile
LLY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Is Eli Lilly And Co. (LLY) Splitting in the Near Future? - Yahoo Finance
Eli Lilly, Avago lead market cap stock movers on Monday - Investing.com
Eli Lilly and Company (NYSE:LLY) Trading Down 4.1%Here's What Happened - MarketBeat
Eli Lilly, Nvidia among Monday's market cap stock movers - Investing.com
Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.
Lilly, Merck team with Purdue University to pioneer new drug production methods - FiercePharma
Pediatric Medicines Market May See a Big Move | Eli Lilly, Johnson & Johnson, Pfizer - openPR
Jim Cramer Says ‘Eli Lilly and Company (LLY)’s Drug Is Superior In Terms Of Weight Reduction At The Same Dose’ - Yahoo Finance
Jim Cramer on Eli Lilly and Company (LLY)’s Q4 2024 Performance: ‘Aren’t As Strong As Wall Street Was Hoping’ - Insider Monkey
Should You Buy the Dip in Eli Lilly Stock Right Now? - MSN
Eli Lilly Faces a Dramatic Stock Plunge! Is This Your Chance to Cash In? - Jomfruland.net
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried? - sharewise
Here’s Why Jim Sees Eli Lilly and Company (LLY) as a Long-Term Buy - Insider Monkey
Why Is Cliff Asness Bullish On Eli Lilly and Company (LLY)? - Insider Monkey
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? - The Motley Fool
Purdue, Lilly and Merck launch new manufacturing collaboration effort - Purdue Exponent
How Is The Market Feeling About Eli Lilly? - Benzinga
Leerink keeps Eli Lilly stock outperform on revenue growth - MSN
Meds made by Novo Nordisk, Pfizer, Eli Lilly among those up for Medicare price negotiations - Sherwood News
Leerink keeps Eli Lilly stock outperform on revenue growth By Investing.com - Investing.com Canada
Eli Lilly stock target cut, retains Buy rating on growth potential - MSN
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY) - StreetInsider.com
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Purdue aims to speed evolution of pharma manufacturing in collaboration with Lilly and Merck - Purdue University
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease - Yahoo Finance
Pace quickens at the Eli Lilly and Co. Lebanon site - Lebanon Reporter
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Burney Co. Has $24.47 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025? - The Motley Fool
FDA approves Lilly’s Omvoh for Crohn’s disease - WISH TV Indianapolis, IN
Eli Lilly & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Eli Lilly's Options: A Look at What the Big Money is Thinking - Benzinga
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today - Benzinga
Crohn’s Gets More Competitive As Lilly Lands Second Omvoh Okay - News & Insights
Lilly IBD biologic receives expanded US approval -January 16, 2025 at 11:01 am EST - Marketscreener.com
Lilly IBD biologic receives expanded US approval - European Pharmaceutical Review
Is Lilly Stock A Sell After Tumbling On Its Guidance Cut? - Investor's Business Daily
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson - BioPharma Dive
Eli Lilly and Co. employees donate food and money to The Caring Center - Lebanon Reporter
Founders Grove Wealth Partners LLC Acquires New Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Eli Lilly and Company (NYSE:LLY) Shares Acquired by Community Trust & Investment Co. - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Josh Gottheimer - MarketBeat
Rep. Josh Gottheimer Sells Eli Lilly and Company (NYSE:LLY) Stock - MarketBeat
US FDA approves expanded use of Lilly's bowel disease drug - Reuters
Today at JP Morgan: Spending Lilly’s billions, GSK’s Blenrep prepped, cautious optimism for China drug deals and a gene therapy breakout - FirstWord Pharma
Eli Lilly's SWOT analysis: stock poised for growth despite challenges - Investing.com
Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment - The Wall Street Journal
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease - Investors | Eli Lilly and Company
Stock Quote & Chart | Eli Lilly and Company - Investors | Eli Lilly and Company
Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh for Crohn's disease - StreetInsider.com
Eli Lilly is considering offering more Zepbound doses in vials at lower cost - STAT
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
5.27%
大文字化:
|
ボリューム (24 時間):